Several TKIs targeting the CSF-1/CSF-1R axis are now being studied for treating advanced solid tumors, including HCC, such as pexidartinib (NCT02452424), chiauranib (NCT03245190), TPX-0022 (NCT03993873), and BLZ945 (NCT02829723). Here, CSF1R is linked to hepatocellular carcinoma.